Semaglutide vs Retatrutide
Semaglutide and retatrutide sit at opposite ends of the incretin receptor spectrum. Semaglutide is a selective single-receptor GLP-1 agonist with the most extensive clinical evidence in its class, while retatrutide engages three receptors: GIP, GLP-1, and glucagon.
Side-by-Side Comparison
| Property | Semaglutide | Retatrutide |
|---|---|---|
| Category | GLP-1 receptor agonist (single agonist) | GIP/GLP-1/glucagon triple receptor agonist ("triple G") |
| Mechanism of Action | Selective GLP-1 receptor activation; stimulates insulin secretion, suppresses glucagon, slows gastric emptying, reduces appetite | Simultaneous GIP, GLP-1, and glucagon receptor activation; combines appetite suppression with increased energy expenditure |
| Molecular Weight | ~4,113 Da | ~4,731 Da |
| Primary Research Focus | Type 2 diabetes, obesity, cardiovascular risk reduction, NASH/MAFLD | Obesity, type 2 diabetes, hepatic steatosis research |
| Receptor Target | GLP-1 receptor (selective) | GIP receptor + GLP-1 receptor + glucagon receptor |
| Half-Life | ~7 days (C-18 fatty diacid, albumin binding) | ~6 days (fatty diacid modification, albumin binding) |
| Key Research Citations | Wilding et al. (2021), STEP-1, NEJM; Lincoff et al. (2023), SELECT, NEJM | Jastreboff et al. (2023), NEJM phase 2 obesity; Rosenstock et al. (2023), Lancet phase 2 T2D |
Key Differences
- Semaglutide activates one receptor (GLP-1R); retatrutide activates three (GIP, GLP-1, glucagon), a fundamentally broader pharmacological approach.
- Retatrutide’s glucagon receptor component adds an energy-expenditure mechanism absent from semaglutide, which acts mainly through appetite and gastric-emptying pathways.
- Semaglutide’s evidence base is far deeper: completed phase 3 programs plus the SELECT cardiovascular outcomes trial. Retatrutide data are primarily phase 2.
- In phase 2, retatrutide reported up to ~24% mean weight reduction at 48 weeks versus ~15% at 68 weeks for semaglutide 2.4 mg in STEP-1, though cross-trial comparisons carry inherent limitations.
Research Summary
Semaglutide is the reference single-receptor GLP-1 agonist, with the largest completed evidence base in metabolic and cardiovascular research. Retatrutide is an investigational triple agonist that layers GIP and glucagon receptor activity on top of GLP-1 agonism, producing the largest weight reductions yet reported in phase 2 obesity research. The comparison illustrates the field’s trajectory from selective single-receptor agonism toward multi-receptor engagement of complementary metabolic pathways.
How does semaglutide compare to retatrutide?
Semaglutide is a selective GLP-1 receptor agonist with completed phase 3 and cardiovascular outcome trials. Retatrutide is an investigational triple agonist targeting GIP, GLP-1, and glucagon receptors; its glucagon component adds increased energy expenditure. Phase 2 retatrutide research reported up to ~24% mean weight reduction at 48 weeks versus ~15% for semaglutide in STEP-1, but retatrutide’s long-term dataset is much smaller.
More Comparisons
Disclaimer: All compounds referenced on this page are sold for research and laboratory use only. The comparisons presented are based on published scientific literature and are intended for educational and informational purposes. This content does not constitute medical advice. Researchers should consult primary literature and applicable regulations before designing study protocols.